Each week, our Regional Roundup delivers the most important and timely life sciences news from around the region. From groundbreaking research to fundraising, new development projects, and who’s hiring — we bring you the top stories that matter most. Stay informed with a curated selection of the latest news, delivered directly to your inbox weekly.
North Carolina life sciences didn’t write one big check this week, it wrote a lot of smaller ones instead. Across financial, clinical, and workforce headlines, the same instinct kept surfacing: prove it first, spread the risk, and don’t fully commit until someone else has already absorbed the downside.
RedHill Biopharma funded its entire $12 million acquisition of Rebyota and Clenpiq’s commercialization rights with cash from its earlier Talicia divestiture — banking one win to buy the next rather than reaching for the balance sheet. Endpoint Clinical ran a version of the same play, acquiring Bluefin but leaving it to operate independently and RTSM-agnostic instead of folding it fully into its own platform — expansion without giving up optionality.
The science and infrastructure followed the same logic. RTI International expanded its Pilot Xcelerator by $14 million specifically so companies like Syzygy Plasmonics and Aether Fuels can prove performance before committing the capital to build that capacity themselves, and Cape Fear BioCapital took the instinct to its extreme, closing Fund I to write seven first checks out of 200-plus opportunities reviewed — spreading a bet across a portfolio instead of concentrating it in one company.
And still, the region isn’t short on full conviction. Novo Nordisk is deep into a $4.1 billion expansion of its Clayton campus, and Genentech tapped Erin Hill to lead material management for its own $2 billion Holly Springs plant — no phased approach on either, just a straight bet on North Carolina.
Financial
Tracking the capital moving through North Carolina— funding rounds, M&A activity, and investment trends shaping NC’s life sciences companies.
Cape Fear BioCapital Closes Fund I to Back North Carolina’s Earliest-Stage Therapeutics Startups
Cape Fear BioCapital, a Research Triangle Park venture firm, has closed Fund I to write first checks into NC’s earliest-stage therapeutics and human-health companies — betting that the state has “everything it needed to build world-class biotech companies except access to early capital,” per co-founder Ed Field. Backed by Moore Strategic Ventures and Parexel, the firm has already made seven investments (including EnFuego Therapeutics) out of 200+ opportunities reviewed, with room for a few more before Fund II. Read More >
Endpoint Clinical Acquires Bluefin, a Provider of Clinical Supply Forecasting and Planning Technology
Endpoint Clinical, a portfolio company of Arsenal Capital Partners and a global leader in randomization and trial supply management (RTSM), has acquired Bluefin, a Boston-based clinical supply forecasting and planning technology provider. The deal expands Endpoint into clinical supply chain planning while Bluefin continues operating independently and RTSM-agnostic, with Endpoint providing global project management, implementation, and support to help sponsors connect supply forecasting to real-time trial execution data. Read More >
UNC Lineberger Secures $40M from OpenAI Foundation to Make Cancer Vaccines More Effective
UNC Lineberger Comprehensive Cancer Center has received $40 million from the OpenAI Foundation to generate clinical data that can train AI models to identify stronger cancer-cell targets and guide development of more effective personalized cancer vaccines. Led by immunologist Benjamin Vincent, MD, and computational biologist Alex Rubinsteyn, PhD, the work will analyze de-identified tumor tissue and immune cell data from three biobanks and compare vaccine formulations in clinical trials for triple-negative breast cancer, as part of the Foundation’s new Public Data for Health initiative to open-source scientific datasets for cancer research. Read More >
People
Who we’re buzzing about this week — the leadership moves, board appointments, and rising names shaping the region’s life sciences community.
Slate Medicines Names Kenneth Koblan Chief Scientific Officer as Migraine Pipeline Advances
Slate Medicines has named Kenneth Koblan, PhD, Chief Scientific Officer, adding more than three decades of drug discovery and development experience as the Raleigh, North Carolina-based company advances SLTE-1009, its lead monoclonal antibody candidate for migraine prevention. Koblan most recently served as head of R&D at Vesalius Therapeutics and spent 13 years at Sumitomo Pharma America (formerly Sunovion), including as Chief Scientific Officer, after earlier senior roles at Merck Research Laboratories and Alnylam Pharmaceuticals. Read More >
Velocity Clinical Research appoints Justin Starzyk as Chief Executive Officer
Velocity Clinical Research has named Justin Starzyk Chief Executive Officer, succeeding Paul Evans, who transitions to Chair of the Board. Starzyk joins from United Urology Group, where he served as President overseeing roughly 300 physicians and 2,000 teammates across 100 locations, following nearly a decade at DaVita and an earlier career in pharmaceutical R&D at Abbott Laboratories and AbbVie, a return to drug development that he called “a homecoming” as he takes the reins at the GHO Capital-backed integrated clinical trial site organization. Read More >
Annie Woodard Joins NCBiotech as Program Manager, Workforce Solutions
Annie Woodard has joined the North Carolina Biotechnology Center as Program Manager, Workforce Solutions, on the Life Sciences Economic Development team, where she’ll lead workforce development programs connecting job seekers, training providers, and employers across North Carolina’s life sciences ecosystem. Woodard joins NCBiotech from Motive Labs, following seven years at RTI International in talent acquisition roles spanning its General and Administrative, Health Solutions, and Discovery Science Technology business units. Read More >
Workforce
The hiring activity, team expansions, and talent trends driving growth across North Carolina’s life sciences and biotech employers.
STERIS to Invest $600M, Bring 335 Jobs to Sanford
STERIS plc, a global provider of infection prevention products and services, plans to invest $600 million to build a 600,000-square-foot Chemistry Manufacturing Center of Excellence at Helix Innovation Park in Sanford, creating 335 jobs — the company’s largest-ever single manufacturing investment. The facility, supported by a $3.2 million JDIG grant, will consolidate STERIS’s chemistries manufacturing and distribution from St. Louis and Plymouth, Minnesota, and becomes the latest life sciences project to land in Lee County alongside Kyowa Kirin, Pfizer, and Astellas Gene Therapies. Read More >
North Carolina’s Medtech Workforce Fuels Industry Growth
North Carolina’s growing medtech sector is being supported by a strong talent pipeline, with five Tier-1 research universities producing more than 6,000 biological and biomedical graduates annually and the state’s community colleges expanding specialized life sciences training. MD+DI explores how workforce development, manufacturing expertise, and targeted training programs are helping North Carolina attract and scale medical device and diagnostics companies. Read More >
Who’s hiring?!
Top Employer
A global healthcare company headquartered in Bagsværd, Denmark, founded in 1923 and focused on diabetes, obesity, and other serious chronic diseases. With more than 69,000 employees across roughly 170 countries, the company develops innovative biological medicines, including insulin and GLP-1 treatments.
Novo Nordisk has operated in North Carolina for more than 30 years, employing over 2,200 people across three facilities. Its Clayton campus manufactures active ingredients for diabetes and weight-management drugs, including semaglutide (Ozempic and Wegovy). The company is investing $4.1 billion in a new 1.4-million-square-foot facility, creating 1,000 jobs and becoming the largest life sciences capital investment in North Carolina history.
They are currently hiring across 65+ roles in the North Carolina region. Apply Now >
Other employers and available roles we’re paying attention to this week:
- IQVIA (Durham, NC) is hiring a Sr. Business Development Director| Apply Now >
- PCI (Raleigh, NC) is hiring a Senior Calibration Technician| Apply Now >
- KBI Biopharma (Durham, NC) is hiring a Microbiology Specialist I | Apply Now >
- Beckton Dickinson (Durham, NC) is hiring a R&D Procurement Manager | Apply Now >
- GSK (Durham, NC) is hiring an Oncology Forecasting Manager | Apply Now >
Clinical + Commercial
The latest clinical trial progress, regulatory milestones, and commercial launches from companies advancing science from the lab to the market across North Carolina.
Veranex and MDIC Launch EFS Explorer to Streamline Early Feasibility Study Site Selection
Veranex, an Innovation CRO headquartered in Raleigh, N.C., has launched EFS Explorer, a new platform developed with the Medical Device Innovation Consortium (MDIC) to help medical device sponsors identify and evaluate clinical research sites for Early Feasibility Studies. Built on ClinicalTrials.gov data and MDIC’s curated EFS resources, the tool centralizes site experience and study history to give sponsors a more efficient, evidence-informed path from clinical strategy to study execution. Read More >
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
RedHill Biopharma has acquired exclusive commercialization rights to Ferring’s Rebyota® and Clenpiq® — two FDA-approved GI drugs that together generated roughly $37.5 million in 2025 net sales, for a $12 million upfront payment funded entirely by RedHill’s previously announced $18 million Talicia divestiture. The deal gives the Raleigh-based specialty biopharma global rights to Rebyota, a first-in-class fecal microbiota therapy for preventing recurrent C. diff infection, and U.S. rights to Clenpiq, a ready-to-drink bowel prep, completing what CEO Dror Ben-Asher called a strategic repositioning into a materially larger, fully controlled GI commercial business. Read More >
RTI International Doubles Down on Research Triangle Park with $14 Million Pilot Xcelerator Expansion
RTI International has completed a $14 million expansion of its Pilot Xcelerator facility on its Research Triangle Park campus, a 25,000-square-foot buildout that doubles the commercialization infrastructure at what RTI calls the only privately owned industrial pilot laboratory in North Carolina. The facility helps energy and industrial innovators bridge the gap from lab-proven technology to commercial scale, with companies including Syzygy Plasmonics, CarbonBridge, Aether Fuels, and Lydian Labs already using the platform to advance sustainable aviation fuel, carbon capture, and power-to-liquids technologies toward commercial deployment. Read More >
Ecosystem
The partnerships, programs, and policy moves building North Carolina’s life sciences infrastructure — and the organizations driving it forward.
Kincell Bio and Cellipont Bioservices Merge to Form Kincellis Advanced Therapies
Kincell Bio and Cellipont Bioservices have completed their merger to form Kincellis Advanced Therapies, a U.S.-based CDMO combining Kincell’s immune-cell technology expertise with Cellipont’s experience across stem cells, iPSCs, MSCs, dendritic cells, and exosomes to support advanced therapies from early development through commercial supply. Led by CEO Darren Head, the combined company operates roughly 140,000 square feet across Gainesville, Florida; Research Triangle Park, North Carolina; and The Woodlands, Texas, with 16 GMP manufacturing suites, more than 200 employees, and a track record of over 150 GMP batch releases, backed by equity financing led by NewSpring Capital and a debt facility from J.P. Morgan. Read More >
Duke-NCCU Bridge Office celebrates Five years of Impact, Partnership, and Community
The Duke-NCCU Bridge Office marked its five-year anniversary on July 30, 2026, gathering roughly 100 guests at the Blue Hill Event Center in Chapel Hill to celebrate the office’s work advancing multidisciplinary research collaboration, workforce development, and community partnerships between the two universities. The evening included a retirement tribute to NCCU’s Faye Calhoun, PhD, whose leadership helped shape the office since its founding, alongside reflections from current researchers and former interns on how the program opened doors to research, mentorship, and career opportunities. Read More >
Other [Good] Reads
Editor’s picks from across the web — the stories, videos, and podcasts shaping the conversation in NC biotech and life sciences this week.
North Carolina Breaks Into Top 10 States for Innovation
North Carolina has broken into the nation’s top 10 states for overall innovation capacity for the first time, ranking 9th nationally according to the North Carolina Department of Commerce’s 2026 Tracking Innovation report. The state’s innovation economy has grown faster than the U.S. overall since the early 2000s, with standout gains in academic R&D output, SBIR/STTR funding for early-stage companies, and knowledge- and technology-intensive business formation — though the report flags persistent gaps in broadband access, school funding, and wage growth relative to the national average. Read More >
Leveraging Medical Analytics to Improve Strategy, Launch, Outcomes and Care Models
Chapel Hill, NC-based Best Practices, LLC’s benchmarking research across 41 Medical Affairs leaders at 38 biopharma organizations found that 85% believe medical analytics can accelerate adoption and reshape care models, yet only 14% say their analytics function is well funded. The gap isn’t a budgeting oversight, it’s governance: 92% of high performers say analytics informs their Medical and Clinical strategy, compared to just 59% of the average organization. Download Now >
Connecting Data, People, and Patients: How AI is Advancing Neuroscience Clinical Trials
AI is transforming neuroscience clinical trials by connecting complex patient data, research teams, and clinical insights to accelerate trial design, improve patient identification, and support more personalized approaches to care. Fortrea explores how AI-powered analytics and digital technologies are helping researchers streamline clinical development and advance innovation in neurological drug development. Read More >
On the Calendar
A few of the upcoming events, conferences, and networking opportunities across North Carolina’s life sciences ecosystem that you don’t want to miss.
WIB-National: Power Connect – Exclusive Members-Only Speed Networking
Friday, September 18, 2026 • 3–4 PM • Online
Hosted by Women in Bio (WIB-National) | Register Now >
Immunohematology Boot Camp: High and Low Prevalence Antigens (26EL-678)
Wednesday, September 30, 2026 • 2–3 PM • Online
Hosted by AABB | Register Now >
2026 Triangle Cytoskeleton Meeting
Monday, September 21, 2026 • 9 AM–6:30 PM • Chapel Hill, NC
Hosted by NCBiotech | Register Now >
Did we miss something!? Drop us a line →
Stay connected to North Carolina’s Region life sciences.
🔍 Explore companies → · 💼 Browse jobs → · 📅 See events → · 📰 Read more →
Get the North Carolina Region Roundup every Friday.
The week’s most important life sciences news from the NC region— delivered to your inbox.
